<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01353833</url>
  </required_header>
  <id_info>
    <org_study_id>P101101</org_study_id>
    <secondary_id>2010-024499-24</secondary_id>
    <nct_id>NCT01353833</nct_id>
  </id_info>
  <brief_title>Dose-effect Relationship of Low-dose IL-2 in Type 1 Diabetes</brief_title>
  <acronym>DF-IL2</acronym>
  <official_title>Dose-effect Relationship of Repeated Administration of Low-dose IL-2 Versus Placebo on the Kinetic of Regulatory T Cells in Patients With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      IL-2 is an inducer of regulatory T cells (Treg), a population of lymphocytes that fail to&#xD;
      control the autoimmune destruction of beta-cells in patients with Type 1 Diabetes (T1D). The&#xD;
      investigators recently showed that low dose IL-2 is well tolerated in patients with an&#xD;
      autoimmune disease. The investigators aim to use IL-2 to induce/stimulate Treg in T1D&#xD;
      patients. This study will investigate the dose effect relationship of low dose IL-2 for Treg&#xD;
      induction such as to optimize the risk benefit ratio for this treatment in T1D. By Treg&#xD;
      induction, the investigators aim to protect the remaining/regenerating β-cells from&#xD;
      autoimmune destruction, thus improving or even curing T1D.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale:&#xD;
&#xD;
      Type 1 diabetes (T1D) results from an autoimmune destruction of beta-pancreatic cells that&#xD;
      regulatory T cells (Treg) fail to control. This is in part due to a deficit in production of,&#xD;
      or response to, interleukin 2 (IL-2). This cytokine is essential to Treg development,&#xD;
      survival and function. Importantly, while IL-2 also contributes to the activation of effector&#xD;
      T cells (Teff), IL-2/IL-2 receptor signal transduction threshold is much lower for Treg than&#xD;
      Teff. Thus low-dose IL-2 could be a specific Treg inducer/stimulator.&#xD;
&#xD;
      The investigators then recently showed that low-dose IL-2 could cure recent onset diabetes in&#xD;
      NOD mice that develop spontaneous diabetes considered as the best model of human T1D. A 5-day&#xD;
      treatment with IL-2 could cure over 30% of the mice versus 0% for controls.&#xD;
&#xD;
      With these premises, the investigators propose to explore if Treg induction could be obtained&#xD;
      in patients who may have a deficit in production of, or response to, IL-2. Defining the dose&#xD;
      effect relationship of low dose IL-2 for Treg induction will optimize the risk benefit ratio&#xD;
      for IL-2 in T1D.&#xD;
&#xD;
      Principal objective:&#xD;
&#xD;
      To define the dose-effect relationship of low dose IL-2 for Treg induction in patient with&#xD;
      recent onset diabetes&#xD;
&#xD;
      Evaluation Criteria:&#xD;
&#xD;
        -  Efficacy Kinetic variation of Treg proportions within CD4+ T cells in peripheral blood&#xD;
           from Day+0 to Day+60.&#xD;
&#xD;
        -  Tolerance Evaluation by clinical exams, laboratory tests and monitoring of side effects.&#xD;
           The criterion for terminating the study will be the occurrence of one serious unexpected&#xD;
           side effect in the month following IL-2 first administration in at least 2 patients.&#xD;
&#xD;
      Study plan:&#xD;
&#xD;
      After inclusion (Day0), the patient receives a 5-day course of IL-2 or placebo. Patients are&#xD;
      randomized in 4 arms receiving either a placebo, or IL-2 doses of 0,33 - 1 or 3 millions&#xD;
      UI/day. Laboratory follow-up of peripheral blood T cell subsets will be performed at D0 to D6&#xD;
      (daily), D15, D22 and D60 by immunophenotyping and transcriptomics.&#xD;
&#xD;
      Tolerance will be evaluated at D0-6, D15, D22 and D60.&#xD;
&#xD;
      Methodology:&#xD;
&#xD;
      Double blind placebo controlled randomized study, with 4 parallel groups. Patients will have&#xD;
      T1D of autoimmune origin attested by the presence of auto-antibodies (at least one of:&#xD;
      anti-islet, anti-GAD, anti-IA2 or anti-ZnT8), with a diagnostic inferior or equal to 24&#xD;
      months.&#xD;
&#xD;
      Study length:&#xD;
&#xD;
      Study length = 9 months Patient participation = 2 months Inclusion period = 6 months&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Kinetic parameters of Treg proportions variation within CD4+ T cells in peripheral blood</measure>
    <time_frame>from Day+0 to Day+60</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of residual secretion of insulin assessed by the AUC of peptide C during a standardized test meal in IL-2 vs placebo treated patients</measure>
    <time_frame>at Day+0 and Day+60</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>IL2-4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IL2-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 millions IU of IL-2 per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IL2-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 millions IU of IL-2 per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IL2-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.33 millions IU of IL-2 per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aldesleukin</intervention_name>
    <description>0.33 ; 1 ; 3 ; 0 millions IU of IL-2 per day for arm 1 to 4, respectively. 1 s.c. injection per day for 5 days.</description>
    <arm_group_label>IL2-1</arm_group_label>
    <arm_group_label>IL2-2</arm_group_label>
    <arm_group_label>IL2-3</arm_group_label>
    <arm_group_label>IL2-4</arm_group_label>
    <other_name>IL2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age [18-50] years;&#xD;
&#xD;
          -  With a T1D:&#xD;
&#xD;
          -  Treated with insulin for ≤ 2 years,&#xD;
&#xD;
          -  With at least one auto-antibody among: anti-islet, anti-GAD, anti-IA2, anti-ZnT8 ;&#xD;
&#xD;
          -  No clinically relevant abnormal value for hematology, biochemistry, liver and kidney&#xD;
             function&#xD;
&#xD;
          -  Lymphocyte [1000-4000]/ mm3&#xD;
&#xD;
          -  Informed consent signed by the patient and the investigator before any intervention&#xD;
             necessary for the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contra-indications to IL2 :&#xD;
&#xD;
          -  Hypersensibility to IL-2 or its excipients,&#xD;
&#xD;
          -  Severe cardiopathy&#xD;
&#xD;
          -  Ongoing infection requiring antibiotherapy,&#xD;
&#xD;
          -  O2 Saturation ≤ 90 %&#xD;
&#xD;
          -  Severe impairment of a vital organ&#xD;
&#xD;
          -  Previous organ allograft&#xD;
&#xD;
          -  Non authorized concomitant treatment : i.e. immuno-modulators, cytotoxic, drug&#xD;
             modifying glycemia&#xD;
&#xD;
          -  Cancer progressing or cured for less than 5 years except for primary basal cell&#xD;
             carcinoma or carcinoma in situ of the uterine cervix.&#xD;
&#xD;
          -  Participation to another clinical investigation in &lt; 3 months&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Male or female in age of procreation without efficient contraception during the study&#xD;
&#xD;
          -  No affiliation to National Health Insurance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Davis Klatzmann, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>May 12, 2011</study_first_submitted>
  <study_first_submitted_qc>May 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2011</study_first_posted>
  <last_update_submitted>April 20, 2012</last_update_submitted>
  <last_update_submitted_qc>April 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

